Jazz Pharmaceuticals Plc Stock Price, News & Analysis

Jazz Pharmaceuticals reported strong Q2 2022 results with total revenues of $932.9 million, a 24% increase year-over-year. The company affirmed its 2022 revenue guidance of $3.5 to $3.7 billion. Notably, Xywav sales surged 89% to $235 million, while Xyrem sales fell 19% to $269.4 million, marking a shift in patient preference. The company achieved a net leverage ratio of 3.2x, ahead of schedule. Additionally, the FDA cleared JZP815 for clinical development, expanding Jazz's oncology pipeline. Adjusted EPS for the quarter rose to $4.30.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is set to report its 2022 second quarter financial results on August 3, 2022, after U.S. market close. A live audio webcast will occur at 4:30 p.m. ET for a financial update and discussion of results. Interested parties can register in advance through Jazz's website. Jazz Pharmaceuticals is committed to developing life-changing medicines in neuroscience and oncology, with a global presence and innovative therapies.

Jazz Pharmaceuticals announced top-line results from the Phase 3 RELEASE MSS1 trial evaluating nabiximols oromucosal spray (JZP378) for multiple sclerosis spasticity. The trial did not meet its primary endpoint of changing Lower Limb Muscle Tone-6 at Day 21. Despite this setback, Jazz remains committed to the nabiximols program, with plans to present data at a future medical meeting. The ongoing Phase 3 trials, RELEASE MSS3 and RELEASE MSS5, aim to supplement this data. Nabiximols has been approved in 29 countries but is not yet FDA-approved in the U.S.

Jazz Pharmaceuticals announced positive results from a Phase 2/3 trial of Rylaze (asparaginase erwinia chrysanthemi) in treating acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). Conducted in collaboration with the Children's Oncology Group, the trial showed that over 90% of patients achieved clinically meaningful nadir serum asparaginase activity. The findings support a new intramuscular dosing schedule aligned with current clinical practices. Rylaze, approved in 2021 for patients with hypersensitivity to E. coli-derived asparaginase, is set to enhance treatment options.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in the Jefferies Healthcare Conference on June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST in New York. An audio webcast of the presentation will be accessible via the Jazz Pharmaceuticals website, with a replay available for 30 days. Jazz Pharmaceuticals is committed to developing innovative treatments for serious diseases and operates globally, serving nearly 75 countries. For more details, visit their official site or follow @JazzPharma on Twitter.

Jazz Pharmaceuticals announced the presentation of 17 new abstracts at SLEEP 2022, from June 4-8, 2022, highlighting advancements in research related to narcolepsy and idiopathic hypersomnia. Key presentations include efficacy analyses of Xywav, a treatment for idiopathic hypersomnia, and interim data from ongoing studies. The research aims to enhance patient understanding and care for these severe sleep disorders, reflecting Jazz's commitment to addressing unmet needs in sleep medicine.

Jazz Pharmaceuticals will present seven abstracts at the ASCO Annual Meeting from June 3-7, 2022, and eight at the EHA Congress from June 9-12, 2022. Key data includes findings on Rylaze in treating acute lymphoblastic leukemia and lymphoblastic lymphoma. An oral presentation will cover the efficacy and safety of Rylaze administered intramuscularly, while several posters will feature data on Zepzelca, Vyxeos, and other therapies. The presentations reflect Jazz's commitment to addressing unmet patient needs in oncology through research advancement.

Axsome Therapeutics has completed the U.S. acquisition of Sunosi (solriamfetol) from Jazz Pharmaceuticals, enhancing its CNS product portfolio. Sunosi, approved by the FDA for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, boasts broad insurance coverage for 96% of commercial lives. The acquisition positions Axsome as a commercial neuroscience company, supporting patient access through comprehensive affordability programs. Clinical trials have shown significant efficacy for Sunosi, including up to 22% reduction in daytime sleepiness and increased wakefulness. Axsome plans further research into Sunosi.

Jazz Pharmaceuticals has successfully completed the divestiture of Sunosi (solriamfetol) in the U.S. to Axsome Therapeutics for an upfront payment of $53 million. Jazz will receive royalties of high single-digit on U.S. net sales for current indications and mid-single-digit for future indications. This transaction allows Jazz to focus on strategic areas for sustainable growth, as stated by CEO Bruce Cozadd. The ex-U.S. transaction is expected to close within 60 days, enhancing Jazz's commitment to operational excellence and shareholder value.